{"id":"W4415940769","doi":"10.1016/j.annonc.2025.08.2572","title":"1948P Treatment outcomes in patients (pts) with advanced c-Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modifications in the LUMINOSITY trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"AbbVie","keywords":"Phases of clinical research; Conjugate; Wild type; Overall survival; Adverse effect; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006053518,0.000340312,0.0008691218,0.0001122218,0.0001790155,0.000655721,0.0002561141,0.0005096571,0.00195195],"category_scores_gemma":[0.0006246283,0.0001478433,0.001036727,0.0002328855,0.0003024608,0.0005937314,0.0002917389,0.001325651,0.0003638972],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007194555,"about_ca_system_score_gemma":0.0004535751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007320236,"about_ca_topic_score_gemma":0.002194998,"domain_scores_codex":[0.9997749,0.00009450559,0.00001272412,0.00004189495,0.00002129396,0.00005468583],"domain_scores_gemma":[0.9997627,0.00005528626,0.00005277802,0.00001728574,0.00001429427,0.0000976198],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7749258,0.004190289,0.08365557,0.000481779,0.003487527,0.0003468461,0.000161817,0.003491357,0.010991,0.00062513,0.005698005,0.1119448],"study_design_scores_gemma":[0.3603543,0.2654116,0.345326,0.0001780968,0.005558676,0.0007256824,0.0002916055,0.004519118,0.003326281,0.00181829,0.01238762,0.0001026968],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961027,0.00124684,0.000116213,0.0003450756,0.00008372535,0.00007654956,0.0006680615,0.000013058,0.001347789],"genre_scores_gemma":[0.9966238,0.0004777064,0.0001052829,0.0003635249,0.00007314688,0.00008365339,0.001263566,0.000005147524,0.001004203],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00195195,"threshold_uncertainty_score":0.006529987,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09948266861913178,"score_gpt":0.4488569971105554,"score_spread":0.3493743284914236,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}